cis-3-(2-Chloro-3,3,3-trifluoroprop-1-en-1-yl)-2,2-dimethylcyclopropanecarboxylic acid | CAS:72748-35-7

We serve cis-3-(2-Chloro-3,3,3-trifluoroprop-1-en-1-yl)-2,2-dimethylcyclopropanecarboxylic acid CAS:72748-35-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
cis-3-(2-Chloro-3,3,3-trifluoroprop-1-en-1-yl)-2,2-dimethylcyclopropanecarboxylic acid

Chemical Name:cis-3-(2-Chloro-3,3,3-trifluoroprop-1-en-1-yl)-2,2-dimethylcyclopropanecarboxylic acid
CAS.NO:72748-35-7
Synonyms:cis-3-(2-Chloro-3,3,3-trifluoroprop-1-en-1-yl)-2,2-dimethylcyclopropanecarboxylic acid
Z-(1R,S)-cis-2,2-dimethyl-3-(2,2-chloro-3,3,3-trifluoro-1-propenyl)cyclopropanecarboxylic acid
 
Physical and Chemical Properties:
Density 1.5±0.1 g/cm3
Boiling Point 271.6±40.0 °C at 760 mmHg
Melting Point 107-109ºC
Molecular Formula C9H10ClF3O2
Molecular Weight 242.623
Flash Point 118.1±27.3 °C
Vapour Pressure 0.0±1.2 mmHg at 25°C
Index of Refraction 1.511
 
Specification:
Appearance:White to off-white crystal
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Tefluthrin(CAS:79538-32-2)Bifenthrin(82657-04-3)Cyhalothrin(CAS:91465-08-6).



Contact us for information like cis-3-(2-Chloro-3,3,3-trifluoroprop-1-en-1-yl)-2,2-dimethylcyclopropanecarboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Z-(1R,S)-cis-2,2-dimethyl-3-(2,2-chloro-3,3,3-trifluoro-1-propenyl)cyclopropanecarboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Z-(1R,S)-cis-2,2-dimethyl-3-(2,2-chloro-3,3,3-trifluoro-1-propenyl)cyclopropanecarboxylic acid Use and application,Z-(1R,S)-cis-2,2-dimethyl-3-(2,2-chloro-3,3,3-trifluoro-1-propenyl)cyclopropanecarboxylic acid technical grade,usp/ep/jp grade.


Related News: According to Apple’s website, all 42 stores will be closed until February 9. The website still works for customers in China.1-fluoro-4-(trifluoromethoxy)benzene manufacturer The first case of the 2019 novel coronavirus in Massachusetts has been confirmed in a man returning from Wuhan, China who is in his 20s and lives in Boston. The Massachusetts Department of Public Health (DPH) and the Boston Public Health Commission (BPHC) were notified by the US Centers for Disease Control and Prevention (CDC) of the positive test results late Friday evening. This is the eighth case of infection with 2019 novel coronavirus reported in the United States. The risk to the public from the 2019 novel coronavirus remains low in Massachusetts.3,3'-Dibromo-1,1'-biphenyl supplier The first case of the 2019 novel coronavirus in Massachusetts has been confirmed in a man returning from Wuhan, China who is in his 20s and lives in Boston. The Massachusetts Department of Public Health (DPH) and the Boston Public Health Commission (BPHC) were notified by the US Centers for Disease Control and Prevention (CDC) of the positive test results late Friday evening. This is the eighth case of infection with 2019 novel coronavirus reported in the United States. The risk to the public from the 2019 novel coronavirus remains low in Massachusetts.2,3-Dimercaptobutane vendor In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.